New insights into the complex dynamics of opioid use following curative-intent cancer surgery reveal a concerning trend in long-term opioid prescriptions among patients initially opioid-naïve before their diagnosis. Emerging from an observational study focusing on U.S. Veterans, this research accentuates the persisting challenge of balancing effective pain management with minimizing the risks of opioid dependency and adverse outcomes in cancer care. Published in the prestigious peer-reviewed journal CANCER, the investigation offers a rigorous assessment of prescription patterns and associated risk factors that illuminate critical considerations for clinicians navigating postoperative pain control.
In the realm of oncologic surgery, especially in early-stage cancers (ranging from stage 0 to 3), managing pain effectively remains a crucial component of patient care, often necessitating opioid analgesics. However, the therapeutic use of opioids carries a non-negligible risk of persistent opioid use, opioid use disorder, and in extreme cases, fatal overdose. This study focuses on 9,213 Veterans who had no opioid prescriptions in the year preceding their cancer diagnosis, thereby establishing a clear baseline to evaluate new opioid initiations and prolonged use post-surgery.
A particularly alarming finding from this cohort was that 10.6% of these patients exhibited new persistent opioid use within the year following their curative-intent surgery. This percentage underscores a significant number of patients transitioning from acute postoperative pain management into extended opioid dependency. Persistent opioid use post-cancer surgery signals complicated clinical trajectories wherein initial pain control strategies may inadvertently contribute to long-term medication reliance, necessitating urgent attention within clinical oncology and pain management protocols.
Moreover, the study identified a subset of patients who were subjected to co-prescriptions of opioids and benzodiazepines—366 Veterans, equivalent to 4.0% of the study population. This co-administration raises critical safety concerns due to the synergistic depressant effects on the central nervous system, markedly increasing risks for respiratory depression, overdose, and even death. The findings strongly suggest an imperative for stringent prescription oversight and clinical guidelines that prevent the hazardous combination of these psychoactive substances during cancer treatment.
The intensity and duration of opioid exposure during the cancer treatment period were also significantly linked to adverse outcomes. Patients receiving higher opioid prescription doses and longer treatment durations had a greater probability of continued opioid use beyond the immediate postoperative period. This dose-response relationship emphasizes the pharmacological principles of tolerance and physical dependence, which can escalate the challenge of opioid tapering and discontinuation in cancer survivors.
Several patient-related factors were associated with elevated risks of post-surgical opioid persistence. Notably, individuals with a documented history of chronic pain prior to their cancer diagnosis demonstrated susceptibility to prolonged opioid use, likely reflecting pre-existing neurobiological sensitization and complex pain syndromes. Additionally, patients burdened with comorbid conditions, including mental health disorders and other chronic illnesses, exhibited increased likelihood of continued opioid consumption, highlighting the multifactorial nature of opioid risk in oncology populations.
Socioeconomic disparities emerged as another critical determinant. Patients with lower socioeconomic status appeared disproportionately affected by persistent opioid use, reflecting broader systemic issues including access to alternative pain management modalities, health literacy, and social determinants of health. This disparity underscores the necessity of tailored interventions aimed at vulnerable populations to ensure equitable, safe, and effective pain control post-cancer treatment.
Adjuvant chemotherapy, often administered following surgery to mitigate cancer recurrence risk, was also correlated with sustained opioid prescriptions. The additive burden of chemotherapy-induced neuropathy and related toxicities likely exacerbates pain symptoms, complicating analgesic management and potentially entrenching opioid dependence. This intersection of multimodal cancer therapies presents a challenging therapeutic landscape where precision in pain management strategies is vital.
From a clinical perspective, these findings advocate for the minimization of opioid exposure without compromising pain control efficacy. The development and implementation of multimodal analgesic protocols—including non-opioid pharmacotherapy, interventional pain techniques, and integrative modalities—represent vital strategies to reduce opioid reliance. Moreover, systematic patient risk stratification, close monitoring, and timely opioid tapering protocols can collectively mitigate long-term opioid-related harms in cancer survivors.
The study’s lead author, Dr. Marilyn M. Schapira of the University of Pennsylvania, emphasizes the dual necessity of effective analgesia balanced against opioid stewardship. As survivorship improves and a growing population of cancer survivors live long term, optimizing pain management while reducing risks of opioid misuse is of paramount importance. This research serves as a crucial call to action for oncologists, surgeons, and pain specialists to refine opioid prescribing practices in the postoperative oncology setting.
The implications extend beyond individual patient care to influence policy-level interventions. Guidelines on opioid prescribing tailored to cancer populations and enhanced educational programs for healthcare providers are urgently needed to address this public health concern. Furthermore, integrating electronic health record alerts and prescription monitoring programs can provide real-time decision support, enhancing safe prescribing patterns and patient outcomes.
In summation, this comprehensive observational study illuminates the complex interplay between cancer treatment, pain management, and opioid prescription safety. Addressing these challenges requires a multidisciplinary approach combining clinical vigilance, patient-centered care, and systemic reforms. Through such concerted efforts, it may be possible to balance the imperative of pain relief with the critical goal of minimizing opioid-related morbidity and mortality in cancer survivors.
Subject of Research: Opioid prescription patterns and persistent opioid use following curative-intent cancer surgery among opioid-naïve U.S. Veterans.
Article Title: The impact of opioid use associated with curative‐intent cancer surgery on safe opioid prescribing practice among veterans: An observational study
News Publication Date: 8-Sep-2025
Web References:
References:
Schapira MM, Chhatre S, Dow PM, et al. The Impact of Opioid Use Associated with Curative Intent Cancer Surgery on Safe Opioid Prescribing Practice among Veterans: An Observational Study. CANCER. Published online September 8, 2025. DOI: 10.1002/cncr.70009.
Keywords:
Opioids, Cancer, Pain, Surgery, Cancer treatments, Persistent opioid use, Opioid prescribing, Benzodiazepines, Chronic pain, Veterans, Adjuvant chemotherapy, Opioid safety
